The AssayMAP Bravo
AssayMAP Bravo Protein Sample Prep Platform
The AssayMAP Bravo platform combines precision liquid flow control, microchromatography cartridges with diverse resin chemistries, and intuitive software to bring the power of chromatography to sample preparation. The system is tailored to address the wide variety of protein sample preparation workflows used in proteomics and biotherapeutic drug discovery and development.
Automated protein sample preparation with the AssayMAP Bravo minimizes variability, sample handling errors, and manual labor. Pre-optimized protocols and permission levels provide a walk-up solution that makes automation accessible for everyone with minimal training. Optional compliance enabling features allow workflows to be seamlessly passed from noncompliant to compliant labs, making the AssayMAP Bravo the ideal automated sample preparation solution for every stage of the drug discovery process.
Automated protein sample preparation with the AssayMAP Bravo minimizes variability, sample handling errors, and manual labor. Pre-optimized protocols and permission levels provide a walk-up solution that makes automation accessible for everyone with minimal training. Optional compliance enabling features allow workflows to be seamlessly passed from noncompliant to compliant labs, making the AssayMAP Bravo the ideal automated sample preparation solution for every stage of the drug discovery process.
Product Details
Features
- AssayMAP Bravo combines precision liquid handling with microchromatography on column-like, resin-filled cartridges to address many sample preparation workflows
- A wide range of cartridge chemistries and sizes addresses many experimental needs in the biopharma industry and beyond
- Reproducible, scalable, and robust liquid handling system with intuitive, easy-to-use operating software
- Pre-optimized protocols and permission-level control enable walk-up operation with minimal training needed
- Application areas include protein purification, phosphoproteomics, protein–protein interactions, immunopeptidomics, antibody drug conjugates (ADC), biomarker discovery, biologics, multiomics, and pharmacokinetics
- Automatic report generation captures the key steps executed during sample preparation
- Proven performance with hundreds of peer-reviewed publications (see AssayMAP Bravo citation index)
- The chromatographic format of AssayMAP cartridges has many advantages compared to magnetic beads, such as a shorter diffusion path, which is beneficial for efficient binding of large molecules
- Seamless transfer of assays between nonregulated and 21 CFR Part 11 regulated labs, which is made possible with compliance-enabling software features
- Semi-automated loading of Evosep Evotip Pure tips enables nanoflow mass spectrometry using the Evosep One instrument and Agilent LC/MS systems
How It Works
Applications
Featured References
- Publications
-
- Monitoring mAb proteoforms in mouse plasma using an automated immunocapture combined with top-down and middle-down mass spectrometry. Jonathan Dhenin, Valérie Lafont, Mathieu Dupré, Alain Krick, Christine Mauriac, and Julia Chamot-Rooke. Proteomics 2024, 24(3-4), e2300069 Learn More
- High-throughput mass spectrometry maps the sepsis plasma proteome and differences in patient response. Yuxin Mi, Katie L. Burnham, Philip D. Charles, Raphael Heilig, Iolanda Vendrell, Justin Whalley, Hew D. Torrance, David B. Antcliffe, Shaun M. May, Matt J. Neville, Georgina Berridge, Paula Hutton, Cyndi G. Geoghegan, Jayachandran Radhakrishnan, Alexey I. Nesvizhskii, Fengchao Yu, GAinS Investigators, Emma E. Davenport, Stuart McKechnie, Roger Davies, David J. P. O’Callaghan, Parind Patel, Ana G. del Arroyo, Fredrik Karpe, Anthony C. Gordon, Gareth L. Ackland, and Charles J. Hinds, Roman Fischer, and Julian C. Knight. Science Translational Medicine 2024, 16(750) eabh0185 Learn More
- The proteogenomic landscape of multiple myeloma reveals insights into disease biology and therapeutic opportunities. Evelyn Ramberger, Valeriia Sapozhnikova, Yuen Lam Dora Ng, Anna Dolnik, Matthias Ziehm, Oliver Popp, Eric Sträng, Miriam Kull, Florian Grünschläger, Josefine Krüger, Manuela Benary, Sina Müller, Xiang Gao, Arunima Murgai, Mohamed Haji, Annika Schmidt, Raphael Lutz, Axel Nogai, Jan Braune, Dominik Laue, Christian Langer, Cyrus Khandanpour, Florian Bassermann, Hartmut Döhner, Monika Engelhardt, Christian Straka, Michael Hundemer, Dieter Beule, Simon Haas, Ulrich Keller, Hermann Einsele, Lars Bullinger, Stefan Knop, Philipp Mertins, and Jan Krönke. Nature Cancer 2024, 5, 1267-1284 Learn More
- Decrypting lysine deacetylase inhibitor action and protein modifications by dose-resolved proteomics. Yun-Chien Chang, Christian Gnann, Raphael R. Steimbach, Florian P. Bayer, Severin Lechner, Amirhossein Sakhteman, Miriam Abele, Jana Zecha, Jakob Trendel, Matthew The, Emma Lundberg, Aubry K. Miller, and Bernhard Kuster. Cell Reports 2024, 43(6), 114272 Learn More
- Predicting treatment outcome using kinome activity profiling in HER2+ breast cancer biopsies. Donna O. Debets, Erik L. de Graaf, Marte C. Liefaard, Gabe S. Sonke, Esther H. Lips, Anna Ressa, and Maarten Altelaar. iScience 2024, 27(6), 109858 Learn More
- The physiological interactome of TCR-like antibody therapeutics in human tissues. Estelle Marrer-Berger, Annalisa Nicastri, Angelique Augustin, Vesna Kramar, Hanqing Liao, Lydia Jasmin Hanisch, Alejandro Carpy, Tina Weinzierl, Evelyne Durr, Nathalie Schaub, Ramona Nudischer, Daniela Ortiz-Franyuti, Ekaterina Breous-Nystrom, Janick Stucki, Nina Hobi, Giulia Raggi, Lauriane Cabon, Emmanuelle Lezan, Pablo Umaña , Isaac Woodhouse, Alexander Bujotzek, Christian Klein, and Nicola Ternette. Nature Communications 2024, 15, 3271 Learn More
- Nonclinical immunogenicity risk assessment for knobs-into-holes bispecific IgG1 antibodies. Wen-Ting K. Tsai, Yinyin Li, Zhaojun Yin, Peter Tran, Qui Phung, Zhenru Zhou, Kun Peng, Dan Qin, Sien Tam, Christoph Spiess, Jochen Brumm, Manda Wong, Zhengmao Ye, Patrick Wu, Sivan Cohen, and Paul J. Carter. mAbs 2024, 16(1), 2362789 Learn More
- IMBAS-MS Discovers Organ-Specific HLA Peptide Patterns in Plasma. Maria Wahle, Marvin Thielert, Maximilian Zwiebel, Patricia Skowronek, Wen-Feng Zeng, and Matthias Mann. Molecular and Cellular Proteomics 2024, 23(1), 100689 Learn More
- Illuminating phenotypic drug responses of sarcoma cells to kinase inhibitors by Phosphoproteomics. Chien-Yun Lee, Matthew The, Chen Meng, Florian P Bayer, Kerstin Putzker, Julian Müller, Johanna Streubel, Julia Woortman, Amirhossein Sakhteman, Moritz Resch, Annika Schneider, Stephanie Wilhelm, and Bernhard Kuster. Molecular Systems Biology 2024, 20(1), 28-55 Learn More
- Systematic discovery of neoepitope–HLA pairs for neoantigens shared among patients and tumor types. Hem R. Gurung, Amy J. Heidersbach, Martine Darwish, Pamela Pui Fung Chan, Jenny Li, Maureen Beresini, Oliver A. Zill, Andrew Wallace, Ann-Jay Tong, Dan Hascall, Eric Torres, Andy Chang, Kenny ‘Hei-Wai’ Lou, Yassan Abdolazimi, Christian Hammer, Ana Xavier-Magalhães, Ana Marcu, Samir Vaidya, Daniel D. Le, Ilseyar Akhmetzyanova, Soyoung A. Oh, Amanda J. Moore, Uzodinma N. Uche, Melanie B. Laur, Richard J. Notturno, Peter J. R. Ebert, Craig Blanchette, Benjamin Haley, and Christopher M. Rose. Nature Biotechnology 2024, 42, 1107-1117 Learn More
